Julian Baker, Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), bought 112,547 shares at $186.59 ($21.2M) on 2023-11-21, disclosed to the SEC on 2023-11-21.
Open-market purchase of $21.2M MDGL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $183.16 | 31 | $6K | 0.0% |
| 2 | $183.16 | 369 | $68K | 0.3% |
| 3 | $183.16 | 369 | $68K | 0.3% |
| 4 | $185.94 | 146 | $27K | 0.1% |
| 5 | $185.94 | 12 | $2K | 0.0% |
| 6 | $186.32 | 647 |
| $121K |
| 0.6% |
| 7 | $186.32 | 53 | $10K | 0.0% |
| 8 | $186.32 | 647 | $121K | 0.6% |
| 9 | $186.59 | 1,385 | $258K | 1.2% |
| 10 | $186.59 | 115 | $21K | 0.1% |
| 11 | $186.59 | 1,385 | $258K | 1.2% |
| 12 | $187.24 | 176 | $33K | 0.2% |
| 13 | $187.24 | 2,124 | $398K | 1.9% |
| 14 | $187.24 | 2,124 | $398K | 1.9% |
| 15 | $187.27 | 388 | $73K | 0.3% |
| 16 | $187.27 | 4,712 | $882K | 4.2% |
| 17 | $187.27 | 4,712 | $882K | 4.2% |
| 18 | $187.27 | 388 | $73K | 0.3% |
| 19 | $188.32 | 13,011 | $2.5M | 11.6% |
| 20 | $188.32 | 1,076 | $203K | 1.0% |
| 21 | $188.32 | 1,076 | $203K | 1.0% |
| 22 | $188.32 | 13,011 | $2.5M | 11.6% |
| 23 | $188.46 | 1,117 | $211K | 1.0% |
| 24 | $188.46 | 1,117 | $211K | 1.0% |
| 25 | $188.46 | 13,505 | $2.5M | 12.0% |
| 26 | $188.46 | 13,505 | $2.5M | 12.0% |
| 27 | $188.70 | 15,620 | $2.9M | 13.9% |
| 28 | $188.70 | 1,291 | $244K | 1.1% |
| 29 | $188.70 | 1,291 | $244K | 1.1% |
| 30 | $190.14 | 7,917 | $1.5M | 7.1% |
| 31 | $190.14 | 655 | $125K | 0.6% |
| 32 | $190.14 | 7,917 | $1.5M | 7.1% |
| 33 | $190.14 | 655 | $125K | 0.6% |
| Total | $188.45 avg | 112,547 | $21.2M | 100% |
| Filing → |
| BCEL | SELL | 2023-10-23 | $211K | — | Filing → |
| IGMS | BUY | 2023-06-28 | $45.0M | — | Filing → |
| INCY | BUY | 2022-02-14 | $213.5M | — | Filing → |